公开(公告)号：US20160264536A1

公开(公告)日：2016-09-15

申请号：US15031505

申请日：2014-10-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki SETO ,  Yoshihiro BANNO ,  Toshihiro IMAEDA ,  Yuichi KAJITA ,  Tomoko ASHIZAWA ,  Masanori KAWASAKI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Izumi NOMURA ,  Takahiko TANIGUCHI ,  Shogo MARUI

IPC: C07D277/56 ,  C07D403/12 ,  C07D239/28 ,  C07D403/04 ,  C07D239/47 ,  C07D239/36 ,  C07D239/52 ,  C07D241/24 ,  C07D498/08 ,  C07D413/04 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D409/04 ,  C07D401/12 ,  C07D239/42

CPC classification number: C07D277/56 ,  C07D239/28 ,  C07D239/36 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/56 ,  C07D241/24 ,  C07D241/26 ,  C07D277/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D498/04 ,  C07D498/08

Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。

公开(公告)号：US20210269420A1

公开(公告)日：2021-09-02

申请号：US17256330

申请日：2019-06-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko FUJIMOTO ,  Koichiro FUKUDA ,  Hiromichi SUGIMOTO ,  Kentaro RIKIMARU ,  Yoshihiro BANNO ,  Takahiro MATSUMOTO ,  Norihito TOKUNAGA ,  Yoshihide TOMATA ,  Yuji ISHICHI ,  Shogo MARUI ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE

IPC: C07D401/14 ,  C07D405/14 ,  C07D211/56

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.